scholarly journals Mesenchymal Stromal Cell-Derived Extracellular Vesicles Protect Against Acute Kidney Injury Through Anti-Oxidation by Enhancing Nrf2/ARE Activation in Rats

2016 ◽  
Vol 41 (2) ◽  
pp. 119-128 ◽  
Author(s):  
Guangyuan Zhang ◽  
Xiangyu Zou ◽  
Yeqing Huang ◽  
Feng Wang ◽  
Shuai Miao ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Extracellular Vesicles ◽  
Mesenchymal Stromal Cell ◽  
Stromal Cell ◽  
Kidney Injury

scholarly journals Pulsed focused ultrasound enhances the therapeutic effect of mesenchymal stromal cell-derived extracellular vesicles in acute kidney injury

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Mujib Ullah ◽  
Daniel D. Liu ◽  
Sravanthi Rai ◽  
Mehdi Razavi ◽  
Waldo Concepcion ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Therapeutic Effect ◽  
Extracellular Vesicles ◽  
Mesenchymal Stromal Cell ◽  
Stromal Cell ◽  
Molecular Mechanisms ◽  
Focused Ultrasound ◽  
Combined Treatment ◽  
Kidney Injury ◽  
Pulsed Focused Ultrasound

Abstract Background Acute kidney injury (AKI) is characterized by rapid failure of renal function and has no curative therapies. Mesenchymal stromal cell (MSC)-derived extracellular vesicles (EVs) are known to carry therapeutic factors, which have shown promise in regenerative medicine applications, including AKI. However, there remains an unmet need to optimize their therapeutic effect. One potential avenue of optimization lies in pulsed focused ultrasound (pFUS), where tissues-of-interest are treated with sound waves. pFUS has been shown to enhance MSC therapy via increased cell homing, but its effects on cell-free EV therapy remain largely unexplored. Methods We combine pFUS pretreatment of the kidney with MSC-derived EV therapy in a mouse model of cisplatin-induced AKI. Results EVs significantly improved kidney function, reduced injury markers, mediated increased proliferation, and reduced inflammation and apoptosis. While pFUS did not enhance EV homing to the kidney, the combined treatment resulted in a superior therapeutic effect compared to either treatment alone. We identified several molecular mechanisms underlying this synergistic therapeutic effect, including upregulation of proliferative signaling (MAPK/ERK, PI3K/Akt) and regenerative pathways (eNOS, SIRT3), as well as suppression of inflammation. Conclusion Taken together, pFUS may be a strategy for enhancing the therapeutic efficacy of MSC-derived EV treatment for the treatment of AKI.

PhaseI/II interim analysis of extracorporeal mesenchymal Stromal cell therapy (SBI-101 Therapy) in subjects with acute kidney injury

Cytotherapy ◽  
2019 ◽  
Vol 21 (5) ◽  
pp. e5
Author(s):  
R. Barcia ◽  
A. Allen ◽  
N. Vaninov ◽  
S. Nguyen ◽  
L. Goodale ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Cell Therapy ◽  
Interim Analysis ◽  
Mesenchymal Stromal Cell ◽  
Stromal Cell ◽  
Kidney Injury

scholarly journals Pulsed Focused Ultrasound Pretreatment Improves Mesenchymal Stromal Cell Efficacy in Preventing and Rescuing Established Acute Kidney Injury in Mice

Stem Cells ◽  
2015 ◽  
Vol 33 (4) ◽  
pp. 1241-1253 ◽  
Author(s):  
Scott R. Burks ◽  
Ben A. Nguyen ◽  
Pamela A. Tebebi ◽  
Saejeong J. Kim ◽  
Michele N. Bresler ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Mesenchymal Stromal Cell ◽  
Stromal Cell ◽  
Focused Ultrasound ◽  
Kidney Injury ◽  
Pulsed Focused Ultrasound ◽  
Ultrasound Pretreatment

scholarly journals Extracorporeal mesenchymal stromal cell therapy (SBI-101) in severe COVID-19 complicated by acute kidney injury

Cytotherapy ◽  
2021 ◽  
Vol 23 (5) ◽  
pp. S20
Author(s):  
J. Teixiera ◽  
M.G. Atta ◽  
L. Noureddine ◽  
S. Nguyen ◽  
B. O’Rourke ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Cell Therapy ◽  
Mesenchymal Stromal Cell ◽  
Stromal Cell ◽  
Kidney Injury

scholarly journals Mesenchymal stromal cell-based therapy in kidney diseases and transplantation

2019 ◽  
Vol 13 (1) ◽  
pp. 3-14
Author(s):  
Federica Casiraghi ◽  
Giuseppe Remuzzi
Keyword(s):  
Acute Kidney Injury ◽  
Kidney Transplantation ◽  
Kidney Disease ◽  
Mesenchymal Stromal Cell ◽  
Stromal Cell ◽  
Kidney Diseases ◽  
Kidney Injury ◽  
Inflammatory Cells ◽  
Renovascular Disease ◽  
Cell Based Therapy

Intense investigation in pre-clinical models of kidney disease and transplantation showed that mesenchymal stromal cell (MSC) therapy acts on renal and inflammatory cells in multiple, complex and integrated ways, resulting in cell repair and regeneration, in the inhibition of inflammatory cells, and in the development of cells endowed with their own anti-inflammatory and immuneregulatory properties. These encouraging data paved the way for exploring the use of MSC in clinics as innovative therapeutic tools for patients with renal diseases and transplantation. In this review, we describe the available results of clinical studies of MSC in patients with post-cardiac surgery, acute kidney injury, chronic kidney diseases - including diabetes, renovascular disease and lupus nephritis - and in kidney transplant recipients, with a particular focus on our experience with MSC therapy as a pro-tolerogenic strategy in kidney transplantation. The available studies, mainly phase 1, indicated that MSC therapy is safe and feasible and not associated with adverse events, at least in the short- and mid-term. Encouraging results have been reported in renovascular disease and kidney transplantation, while studies in acute kidney injury and chronic kidney disease had contrasting outcomes. The relevant issues and the knowledge gap that still limit the translation of MSC cell therapy into clinical practice are discussed briefly.

scholarly journals Mesenchymal stromal cell potency to treat acute kidney injury increased by ultrasound-activated interferon-γ/interleukin-10 axis

2018 ◽  
Vol 22 (12) ◽  
pp. 6015-6025 ◽  
Author(s):  
Scott R. Burks ◽  
Matthew E. Nagle ◽  
Michele N. Bresler ◽  
Saejeong J. Kim ◽  
Robert A. Star ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Mesenchymal Stromal Cell ◽  
Stromal Cell ◽  
Kidney Injury ◽  
Interleukin 10 ◽  
Interferon Γ
Sign in / Sign up

Export Citation Format

Share Document